I totally agree that Eastern (KD) is here to help itself just like any other investor and that is exactly why I think Eastern will likely extend the LoC guarantees in exchange for an increased warrant position and maintenance of the downside protection it currently holds. It has been suggested before that perhaps Eastern would like to gain control of RVX and take Apabetalone all the way through production and distribution. Personally I think this is a ridiculous idea as it would cost 10's if not 100's of millions of dollars of additional capital input to duplicate what big pharma already does well and it would also at the same time needlessly burn years of valuable patent life. Judging from what I have read about KD he is quite shrewd and fully understands the importance of time in an ROI calculation so why would he embark on an adventure that would put increased dollars at risk and at the same time extend time to market. Both of these factors decrease the potential annualized ROI while at the same time increase the overall risk. Again why? To me the most likely two scenarios if BetOnMace is successful are 1) RVX is taken out lock stock and barrel or 2) RVX sells Apabetalone and countinues on as biotech/drug developer. Of course no one knows for sure JMO. For what it's worth, there was discussion regarding whether Apabetalone (post BetOnMace) or Zen-3694 would be the catalyst for value creation in both companies. One other possibility is that the Apabetalone kidney trials, which we are told could be much shorter, show positive increases in kidney function. The unmet need is huge and growing and from what Dr. K-Z said and the positive post hoc eGFR showed, Apabetalone could be a real answer.